Paracetamol Safety Assured: India's Drug Watchdog Dispels Panic Amidst Fever Surge, Promises Vigilant Monitoring

Amidst a noticeable uptick in fever cases across India, including concerns over dengue, malaria, and viral infections, the nation's top drug safety adviser has stepped forward to offer crucial reassurance and clarify the standing on widely used medications like paracetamol. Dr. Rajeev Singh Raghuvanshi, who holds the dual responsibilities of Drug Controller General of India (DCGI) and Secretary-cum-Scientific Director of the Indian Pharmacopoeia Commission (IPC), emphasized that there is absolutely “no need to panic” regarding paracetamol’s safety.

Addressing growing public anxieties and speculative reports, Dr.

Raghuvanshi made it clear that while paracetamol remains a cornerstone for fever management, India's robust drug monitoring system is always active. “If cases of side effects of paracetamol are reported, we will monitor them,” he stated, underlining the proactive approach of the regulatory bodies.

The Indian Pharmacopoeia Commission (IPC) plays a pivotal role in this vigilance.

As the National Coordination Centre (NCC) for the Pharmacovigilance Programme of India (PvPI), the IPC is the central hub for collecting, collating, and meticulously analyzing Adverse Drug Reactions (ADRs) reported across the country. This critical data then informs recommendations made to the Central Drugs Standard Control Organisation (CDSCO), ensuring that any potential safety concerns are addressed swiftly and effectively to safeguard public health.

The current statement comes as a vital clarification, as there have been no specific alerts or reported increases in paracetamol side effects that warrant a change in medical practice.

The emphasis is on maintaining calm and relying on established medical advice, rather than succumbing to misinformation. Paracetamol, prescribed for countless individuals daily, continues to be a safe and effective treatment when used as directed.

Crucially, the drug safety adviser also highlighted the vital role citizens and healthcare professionals play in this monitoring process.

The PvPI offers multiple channels for reporting any suspected adverse drug reactions. These include a toll-free helpline (1800-180-3024), a dedicated PvPI Android app for convenient reporting, and direct submissions to any of the Adverse Drug Reaction Monitoring Centres (AMCs) located nationwide. Every report contributes to a comprehensive understanding of drug safety profiles, making the system stronger and more responsive.

In conclusion, while fevers may be prevalent, the message from India's drug safety authority is one of reassurance and vigilance.

Patients are advised against over-medication and strongly encouraged to consult a doctor if their fever persists beyond two or three days. The system is in place, the monitoring is continuous, and public cooperation in reporting adverse events is key to maintaining the high standards of drug safety in India.